论文部分内容阅读
[目的]探讨局部晚期宫颈癌术前新辅助化疗的临床应用。[方法]采用TP化疗方案,对局部晚期宫颈癌术前新辅助化疗,观察38例患者化疗前后瘤体变化、手术切除率、盆腔淋巴结转移、脉管癌栓、病灶局部变化及病理变化等。[结果]本组总有效率(CR+PR)为84.2%,CR为10.5%,切除率为89.5%。病理报告表现为少许退变癌残留,阳性淋巴结大量坏死组织,癌细胞出现角化珠及退变坏死。[结论]TP联合化疗方案作为新辅助化疗显然比传统治疗方案有明显优势,可减小肿瘤的体积和范围,降低肿瘤临床分期,提高手术率。
[Objective] To investigate the clinical application of neoadjuvant chemotherapy for locally advanced cervical cancer. [Methods] TP chemotherapy was used to treat preoperative neoadjuvant chemotherapy in locally advanced cervical cancer. The changes of tumor, surgical resection rate, pelvic lymph node metastasis, local invasion and pathological changes of 38 patients were observed before and after chemotherapy. [Results] The total effective rate (CR + PR) was 84.2%, CR was 10.5%, and the resection rate was 89.5%. Pathological findings showed a small residual cancer residues, a large number of positive lymph nodes necrosis, cancer cells appear degeneration and necrosis. [Conclusion] TP combined chemotherapy as neoadjuvant chemotherapy obviously has obvious advantages over traditional treatment, which can reduce the size and scope of the tumor, reduce the clinical staging of the tumor and improve the operation rate.